HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
zegcS8N5WrzxzACp